GSK outlines $30bn, five-year plan for R&D and manufacturing in the US
The company’s investment strategy will also encompass AI, digital technology and supply chain infrastructure.
List view / Grid view
The company’s investment strategy will also encompass AI, digital technology and supply chain infrastructure.
Expanding its collaboration with the US biotech will add novel molecular glue degrader-based medicines to the pharma company’s pipeline.
He takes over at the CRO from Peter Benton and brings experience from GHO Capital, Syneos Health and INC Research.
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
The October event at Messe Frankfurt is expected to welcome more than 63,000 pharmaceutical professionals.
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
The new Thousand Oaks, California facility will incorporate advanced automation and digital capabilities.
David Weinreich will also serve as its Chief Medical Officer and arrives at the German pharmaceutical group with experience from Amgen, Bayer and Regeneron.
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.
2 September 2025 | By FUJIFILM Wako Europe GmbH
Watch this webinar to find out how RT-rt PCR is revolutionising sterility testing and discover a unique approach that provides reliable one-day results and enhanced sensitivity and detection capabilities.
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.